Intellia Therapeutics (NTLA) Price & Analysis

Compare

4,657 Followers

NTLA Stock Chart & Stats

$11.74

-$0.56(-4.53%)

At close: Jan 08 4:00 PM EST

$11.74

-$0.56(-4.53%)

Day’s Range― - ―

52-Week Range$5.90 - $28.25

Previous CloseN/A

Volume723.92K

Average Volume (3M)3.51M

Market Cap

$1.32B

Enterprise Value$1.49B

Total Cash (Recent Filing)$511.04M

Total Debt (Recent Filing)$97.97M

Price to Earnings (P/E)―

Beta2.25

Next Earnings

Feb 19, 2026

EPS Estimate

-0.96

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.92

Shares Outstanding115,829,926

10 Day Avg. Volume3,570,235

30 Day Avg. Volume3,512,692

Financial Highlights & Ratios

PEG Ratio0.71

Price to Book (P/B)1.32

Price to Sales (P/S)19.91

P/FCF Ratio-3.25

Enterprise Value/Market Cap1.13

Enterprise Value/Revenue25.90

Enterprise Value/Gross Profit-69.55

Enterprise Value/Ebitda-3.27

Forecast

1Y Price Target

$16.50

Price Target Upside40.55% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering22

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Commercial DemandRapid enrollment in the lonvo-z program signals strong patient demand for a one-time HAE treatment, indicating meaningful commercial upside versus existing chronic therapies.

Durability Of Clinical BenefitLong-term follow-up for lonvo-z demonstrated sustained kallikrein knockdown correlated with prolonged attack-free status, supporting the potential for a durable one-time HAE therapy.

Regulatory PathwayRMAT designation for lonvo-z combined with a fully enrolled Phase III trial strengthens the pathway to an accelerated regulatory filing and could shorten time to market.

Bears Say

Development Cost And Cash RiskRequirements for additional safety trials, longer follow-up, or stricter protocols to address liver safety concerns could raise development costs and strain available cash, pressuring the company's timeline and valuation.

Labeling And Payer RiskPotential for a black box warning or restricted labeling on TTR gene-editing therapy would diminish competitiveness and likely trigger payer resistance to high upfront pricing.

Safety And Regulatory OverhangA fatal liver safety event in the MAGNITUDE study and the ensuing clinical hold have intensified regulatory scrutiny and could substantially delay progress for the TTR program.

Intellia Therapeutics News

Cathie Wood Keeps Loading Up on This Biotech Stock — What’s Driving the Buying Spree?

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) continued to buy shares of Intellia Therapeutics ($NTLA) on Tuesday, extending a...

3h ago

NTLA

Cathie Wood’s ARK Investment buys 40K shares of Intellia Therapeutics today

20:01 EST Cathie Wood’s ARK Investment buys 40K shares of Intellia Therapeutics (NTLA) today Published first on TheFly...

16h ago

NTLA

Cathie Wood Doubles Down on High-Potential Biotech Plays

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio moves on Monday, January 12, as revealed in daily fund...

23h ago

TER

TXG

NTLA, PSNL, KMTUY, ILMN: Cathie Wood Buys Early Biotech Stocks, Cuts Stakes in Illumina

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several portfolio moves across biotech and industrial names on Friday, January 9, 2026....

2d ago

ILMN

NTLA

Intellia Therapeutics price target lowered to $12 from $14 at BofA

BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $12 from $14 and keeps a Neutral...

8d ago

NTLA

Cathie Wood Closes Out 2025 with a Rocket Lab (RKLB) Trim and Fresh Biotech Bets

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several portfolio moves across biotech and growth stocks on Tuesday, December 30,...

14d ago

BEAM

IONS

Synopsys, Reddit, Intellia, Symbotic, Seagate Insider Shock

Insiders have been trading these 5 stocks: (($SNPS)), (($RDDT)), (($NTLA)), (($SYM)) and (($STX)). Here is a breakdown of...

4d ago

STX

SYM

Balancing Promise and Uncertainty: Justifying a Hold on Intellia Ahead of Key Late‑Stage Readouts

William Blair analyst Myles Minter has reiterated their neutral stance on NTLA stock, giving a Hold rating today....

5d ago

NTLA

Intellia Updates Investors on Nex-Z Trial Safety Hold

Intellia Therapeutics ( ($NTLA) ) just unveiled an update. On January 9, 2026, Intellia Therapeutics updated its corporate...

5d ago

NTLA

Citizens JMP healthcare analysts hold an analyst/industry conference

Healthcare Analysts discuss regulatory landscape for AAV-based gene therapies (relevant companies (SLDB, TSHA, BNTC, SRPT, QURE, NTLA, CRSP,...

2M ago

BNTC

CRSP

Algonquin, Spotify, Keysight, Intellia, CoreWeave: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($AQN) ), ( ($SPOT) ), ( ($KEYS) ), ( ($NTLA)...

2M ago

AQN

CRWV

Intellia Therapeutics Reports Q3 2025 Financial Results

Intellia Therapeutics Inc ( ($NTLA) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

NTLA

Midday Fly By: AMD sees acceleration, IBM unveils quantum processor

The major averages were mixed near noon, with the Dow Jones Industrial Average hitting a record high as...

2M ago

Carvana initiated, AT&T upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

NTLA FAQ

What was Intellia Therapeutics’s price range in the past 12 months?

Intellia Therapeutics lowest stock price was $5.90 and its highest was $28.25 in the past 12 months.

What is Intellia Therapeutics’s market cap?

Intellia Therapeutics’s market cap is $1.32B.

When is Intellia Therapeutics’s upcoming earnings report date?

Intellia Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 36 days.

How were Intellia Therapeutics’s earnings last quarter?

Intellia Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.92 earnings per share for the quarter, beating the consensus estimate of -$1.005 by $0.085.

Is Intellia Therapeutics overvalued?

According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Intellia Therapeutics pay dividends?

Intellia Therapeutics does not currently pay dividends.

What is Intellia Therapeutics’s EPS estimate?

Intellia Therapeutics’s EPS estimate is -0.96.

How many shares outstanding does Intellia Therapeutics have?

Intellia Therapeutics has 115,829,926 shares outstanding.

What happened to Intellia Therapeutics’s price movement after its last earnings report?

Intellia Therapeutics reported an EPS of -$0.92 in its last earnings report, beating expectations of -$1.005. Following the earnings report the stock price went down -22.727%.

Which hedge fund is a major shareholder of Intellia Therapeutics?

Currently, no hedge funds are holding shares in NTLA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Intellia Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-52.11%

Trailing 12-Months

Asset Growth

-21.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics (NTLA) Earnings & Revenues

Historic Earnings Reports

NTLA Revenue Breakdown

100.00% Collaboration revenue

NTLA Stock 12 Month Forecast

Average Price Target

$16.50

▲(40.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","16":"$16","29":"$29","42":"$42","55":"$55"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,16,29,42,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.99,12.452307692307691,15.914615384615384,19.376923076923077,22.839230769230767,26.301538461538463,29.763846153846153,33.22615384615384,36.68846153846154,40.15076923076923,43.613076923076925,47.075384615384614,50.5376923076923,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.99,9.567692307692308,10.145384615384616,10.723076923076924,11.30076923076923,11.87846153846154,12.456153846153846,13.033846153846154,13.611538461538462,14.18923076923077,14.766923076923078,15.344615384615384,15.922307692307694,{"y":16.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.99,8.606153846153846,8.222307692307693,7.838461538461539,7.454615384615385,7.070769230769232,6.686923076923077,6.303076923076923,5.9192307692307695,5.535384615384616,5.151538461538462,4.767692307692308,4.383846153846154,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >